●Suzhou Erye Pharmaceutical Co.,Ltd.founded in 1946. It is a diversified and modern high-tech enterprise integrating drug research, production and sales.
●Erye joined Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in 2014 and became the main platform company for anti-coagulant and anti-infective drugs of Fosun Pharma.
●The total number of employees is 1,090, with two production bases, with a total area of 207,385 m² and a building area of 125,288 m².
●Production approvals of 9 APIs(Enoxaparin Sodium,Oxacillin Sodium) and preparations for 66 varieties and 150 specifications (cephalosporins for injection, penicillins for injection,freeze-dried powder for injection and oral dosages).Annual production capacity: 800 billion units Heparins and 5000 kg LMW Heparins ; 400 tons of antibiotics, 400 million powder injections and 100 million capsules.
●Honors: National Science Conference Award for Significant Contributions; National Science Progress Award;China Chemical Pharmaceutical Enterprises in top 100 brands; Anti-infective brand top 10 ;“Famous Trademark of China”ect.
Year of Establishment:
--
Total Assets(USD):
choose not to disclose
Total Number of Staff:
less than 10 person
Main Competitive Advantages:
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
R&D capacity:
Annual Turnover(USD):
choose not to disclose
Main Sales Markets:
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Other Competitive Advantages:
Patents and Copyrights:
Two years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
